Why do so many promising scientific discoveries never become real medicines?

In this episode of Biomedical Frontiers Dr. Mark Esser, Chief Scientific Officer of the Paul and Diane Manning Institute of Biotechnology at the University of Virginia, describes one of the biggest challenges in healthcare innovation: the translational valley of death.

Dr. Esser explains how the Manning Institute is being built to bridge the gap between academic discovery and patient-ready therapies. Drawing on decades of experience in industry, he shares how infrastructure, cross-disciplinary teams, regulatory expertise, and new funding models are essential to turning science into medicine.

The conversation explores:

• Why promising biomedical research often stalls before reaching patients
• How the Manning Institute’s A ...